Artificial intelligence(Al) is transforming research and development across the biohealth sector,

driving gains in R&D productivity and the likelihood of success. 

Translating these advances into real outcomes, however, requires more high-quality data, reduced Al bias, 

faster convergent research across nations and institutions, shared ethical guidelines, 

and clear strategies for applying Al to global public health.

Al-driven biohealth innovation is marked by high uncertainty in its early stages,

large upfront investment, long payback periods, and public-good characteristics such as

shared research infrastructure and data platforms.

As a result, individual corporate investment or traditional finance alone cannot secure sufficient funding.

New Finance is a funding strategy that addresses this gap, 

encompassing Innovative Financing—a financial approach that meets large-scale,

 long-horizon, public-good-type investment needs beyond the reach of any single nation or entity.

Accordingly, this session examines how the public and private sectors can jointly mobilize the capital required

 for Al-driven biohealth innovation through New Finance. 

The discussion opens with aligning national Al-driven biohealth policies with country-specific R&D platforms and global convergent research. 

It then turns to public-private partnership(PPP) models for closing the global biohealth gap and sharing risk,

 global open innovation enabled through New Finance, 

and directions for building a global investment ecosystem that accelerates the market entry and scale-up of innovative technologies. 

The session will share cases of New Finance in practice from global research institutions, 

international organizations, investment firms, and industry, 

with the aim of establishing a sustainable New Finance framework—together with its constituent public-private partnership 

model—for biohealth innovation in the Al era.